{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:53:36Z","timestamp":1775202816496,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005153","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82222062"],"award-info":[{"award-number":["82222062"]}],"id":[{"id":"10.13039\/501100005153","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128286","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:16:27Z","timestamp":1770297387000},"page":"128286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study"],"prefix":"10.1016","volume":"76","author":[{"given":"Xinmo","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lairun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128286_bb0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.apsb.2021.08.017","article-title":"Enterovirus A71 antivirals: past, present, and future","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharmaceut Sin B"},{"key":"10.1016\/j.vaccine.2026.128286_bb0010","first-page":"268","article-title":"Etiological characteristics of hand, foot, and mouth disease caused by enterovirus type 71 or coxsackievirus A16","volume":"11","author":"Han","year":"2016","journal-title":"J Pathogen Biol"},{"key":"10.1016\/j.vaccine.2026.128286_bb0015","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1016\/j.vaccine.2020.05.001","article-title":"WHO working group meeting to develop WHO recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines","volume":"38","author":"Lei","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128286_bb0020","series-title":"Regional Office for the Western P. Hand, foot and mouth disease situation update 2018","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128286_bb0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13020-024-00990-2","article-title":"Analysis of the epidemic characteristics of hand-foot-and-mouth disease and the use of EV71 vaccine in Haizhu district, Guangzhou city from 2017 to 2023","volume":"15","author":"Li","year":"2024","journal-title":"China Med Pharmacy"},{"key":"10.1016\/j.vaccine.2026.128286_bb0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128286_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/14760584.2016.1096782","article-title":"Two- year efficacy and immunogenicity of Sinovac enterovirus 71 vaccine against hand, foot and mouth disease in children","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128286_bb0040","unstructured":"China NHCotPsRo. Technical guidelines for the use of inactivated enterovirus 71 vaccine. In: Beijing, editor. National Health Commission2016."},{"key":"10.1016\/j.vaccine.2026.128286_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.epidem.2021.100506","article-title":"Challenges of evaluating and modelling vaccination in emerging infectious diseases","volume":"37","author":"Madewell","year":"2021","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2026.128286_bb0050","first-page":"1110","article-title":"Immunological surrogate endpoints to evaluate vaccine efficacy","volume":"49","author":"Jin","year":"2015","journal-title":"Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]"},{"key":"10.1016\/j.vaccine.2026.128286_bb0055","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/j.vaccine.2021.03.052","article-title":"Using the power law model to predict the long-term persistence and duration of detectable hepatitis a antibody after receipt of hepatitis a vaccine (VAQTA\u2122)","volume":"39","author":"Martin","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128286_bb0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","article-title":"Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses","volume":"115","author":"David","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2026.128286_bb0065","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1080\/21645515.2015.1118595","article-title":"Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months","volume":"12","author":"Jin","year":"2016","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2026.128286_bb0070","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/21645515.2018.1442997","article-title":"Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation","volume":"14","author":"Hu","year":"2018","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2026.128286_bb0075","doi-asserted-by":"crossref","first-page":"9668","DOI":"10.1016\/j.vaccine.2011.10.018","article-title":"Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines","volume":"29","author":"Liang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128286_bb0080","doi-asserted-by":"crossref","unstructured":"Wang J, Zhang S. Epidemiological characteristics and trends of hand-foot-mouth disease in Shanghai, China from 2011 to 2021. Front Public Health 2023;11.https:\/\/doi.org\/10.3389\/fpubh.2023.1162209.","DOI":"10.3389\/fpubh.2023.1162209"},{"key":"10.1016\/j.vaccine.2026.128286_bb0085","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1016\/j.vaccine.2015.06.050","article-title":"Modeling the long-term antibody response of a hepatitis E vaccine","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128286_bb0090","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/sim.2282","article-title":"A model for immunological correlates of protection","volume":"25","author":"Dunning","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128286_bb0095","unstructured":"World Health Organization. Vaccines and immunization: Investigational vaccine candidate M72\/AS01E. 2024."},{"key":"10.1016\/j.vaccine.2026.128286_bb0100","unstructured":"Burnham KP, Anderson DR. Model Selection and Multi-Model Inference: A Practical-Theoretical Approach2002."},{"key":"10.1016\/j.vaccine.2026.128286_bb0105","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128286_bb0110","first-page":"14","article-title":"Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development","author":"Paramithiotis","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128286_bb0115","doi-asserted-by":"crossref","unstructured":"Plotkin SA. Updates on immunologic correlates of vaccine-induced protection. %J Vaccine 2020;Vol.38:2250\u20137.https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.046.","DOI":"10.1016\/j.vaccine.2019.10.046"},{"key":"10.1016\/j.vaccine.2026.128286_bb0120","doi-asserted-by":"crossref","unstructured":"Krammer F. The human antibody response to influenza a virus infection and vaccination %J Nat Rev Immunol 2019;Vol.19:383\u201397.https:\/\/doi.org\/10.1038\/s41577-019-0143-6.","DOI":"10.1038\/s41577-019-0143-6"},{"key":"10.1016\/j.vaccine.2026.128286_bb0125","doi-asserted-by":"crossref","unstructured":"Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection %J Nat Med 2021;Vol.27:2032\u201340.https:\/\/doi.org\/10.1038\/s41591-021-01540-1.","DOI":"10.1101\/2021.06.21.21258528"},{"key":"10.1016\/j.vaccine.2026.128286_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11050944","article-title":"Immune efficacy of the EV71 vaccine in Fujian Province, China: a real-world analysis of HFMD","volume":"11","author":"Li","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128286_bb0135","first-page":"155","article-title":"Prediction intervals of the COVID-19 cases by HAR models with growth rates and vaccination rates in top eight affected countries: bootstrap improvement","author":"Hwang","year":"2022","journal-title":"Chaos Solitons Fractals"},{"key":"10.1016\/j.vaccine.2026.128286_bb0140","doi-asserted-by":"crossref","unstructured":"Efron B, & Tibshirani, R.J. An introduction to the bootstrap (1st ed.): Chapman and Hall\/CRC; 1994.","DOI":"10.1201\/9780429246593"},{"key":"10.1016\/j.vaccine.2026.128286_bb0145","doi-asserted-by":"crossref","unstructured":"Yang QX, Liu F, Chang L, Lai SY, Teng J, Duan JX, et al. Molecular epidemiology and clinical characteristics of enteroviruses associated HFMD in Chengdu, China, 2013\u20132022. Virology Journal. 2023;20.https:\/\/doi.org\/10.1186\/s12985-023-02169-x.","DOI":"10.1186\/s12985-023-02169-x"},{"key":"10.1016\/j.vaccine.2026.128286_bb0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bsheal.2019.02.005","article-title":"Surveillance, epidemiology, and pathogen spectrum of hand, foot, and mouth disease in mainland of China from 2008 to 2017","volume":"1","author":"Ji","year":"2019","journal-title":"Biosafety Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:44:42Z","timestamp":1775195082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S0264410X26000940"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128286","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128286"}}